Panagene Inc (046210) Fair Value & Analysis
Healthcare · KR · Market cap 54.9B KRW
Fair value as of: Jul 20, 2026
From 1 valuation models · updated 20 days ago
Share price −22.6% over the past month.
Below-average quality, and screening another 57% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (600.45 KRW). The favourable scenario is already priced in.
- Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (317.04 KRW to 600.45 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 999.00 KRW – 6,330 KRW · fair‑value band 317.04 KRW – 600.45 KRW · the 1,106 KRW price screens above the 480.36 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Panagene Inc (046210) currently trades at 1,106 KRW, while our model-based Fair Value estimate is 480.36 KRW, implying the stock looks roughly 56.6% overvalued today. The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Panagene Inc generated revenue of 29.9B KRW at a net margin of -18.8%. Revenue declined 72.2% year over year. Net debt stands at 12.8B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 317.04 KRW (bear case) to 600.45 KRW (bull case); at 1,106 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -13% fair-value upside, at -57%, 046210 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 27 · Market factors (momentum, volatility) 13
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and …
Full company description
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The company was formerly known as Koram Panagene Ltd. and changed its name to Panagene Inc. in January 2009. Panagene Inc. was incorporated in 1976 and is based in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Panagene Inc reported revenue of 15.0B KRW in FY2025 versus 15.6B KRW in FY2021, a compound −0.9%/yr. Reported net income was −3.1B KRW in FY2025.
046210 screens 57% overvalued. Compare with MEDIPOST Co →
Peer Group
Health Care · 2228 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| MEDIPOST Co 078160 | 8,150 KRW | 4,269 KRW | -48% |
| Bioneer Corporation 064550 | 6,020 KRW | 8,312 KRW | +38% |
| Macrogen, Inc 038290 | 11,090 KRW | 4,457 KRW | -60% |
| Cell Biotech Co 049960 | 14,980 KRW | 19,433 KRW | +30% |
| Biotoxtech Co 086040 | 2,010 KRW | 1,481 KRW | -26% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
| GSK plc GSKN | 917.00 MXN | 1,078 MXN | +18% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
Compare Panagene Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Panagene Inc (046210) overvalued or undervalued?
What is the fair value of 046210?
What is the quality score of 046210?
What is the revenue of Panagene Inc (046210)?
What is the net profit margin of 046210?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Panagene Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.